AOA Dx focuses on early-stage cancer detection within the healthcare industry. They provide diagnostic solutions that utilize artificial intelligence and proprietary biomarker technology to identify cancer at an early stage. Its main offering includes the GlycoLocate platform, which employs a multi-omics approach to analyze tumor markers for cancer diagnostics, and the liquid biopsy test, which is used for the detection of ovarian cancer.